EGRX - Eagle Pharmaceuticals (EGRX) Engaged in Accounting Fraud Investor Suit Alleges - Hagens Berman | Benzinga

SAN FRANCISCO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investors who suffered substantial losses to submit your losses now.

Class Period: Aug. 8, 2023 – Nov. 28, 2023
Lead Plaintiff Deadline: Feb. 9, 2024
Visit: www.hbsslaw.com/investor-fraud/EGRX
Contact An Attorney Now: EGRX@hbsslaw.com
                                           844-916-0895

Eagle Pharmaceuticals, Inc. (EGRX) Securities Fraud Class Action:

"The litigation focuses on whether Eagle Pharmaceuticals knew and should have disclosed earlier that it under reserved," said Reed Kathrein, the Hagens Berman partner leading the investigation.

The complaint alleges that, throughout the Class Period, Eagle made false and misleading statements and failed to disclose that: (1) Eagle was experiencing slower-than-anticipated pull-through from a wholesale customer predominantly due to expiry of inventory; (2) as a result, Eagle overstated revenues; and (3) the company lacked effective internal controls ...

EGRX) Engaged in Accounting Fraud, Investor Suit Alleges - Hagens Berman>Full story available on Benzinga.com